KEYNOTE-905 and the Future of MIBC Treatment

The final segment projects how KEYNOTE-905 will shape the next era of bladder cancer care. Experts note that its success underscores the power of multidisciplinary collaboration and signals a shift toward integrating immunotherapy across disease stages. Urologists, oncologists, and radiologists will increasingly work together to deliver seamless perioperative management, ensuring patients receive optimal treatment sequences within coordinated care pathways.

Several unanswered questions remain, including how durable the responses will be, which biomarkers best predict benefit, and how to optimize therapy for different molecular subtypes. As secondary endpoint data mature, clinicians will gain deeper insight into long-term survival and recurrence trends, guiding refinement of treatment algorithms and future trial designs.

Finally, KEYNOTE-905’s influence extends to the broader research landscape. Ongoing studies such as KEYNOTE-866, 992, and B15 are expected to further define the role of immunotherapy and novel combinations in MIBC. Together, these trials may establish a continuum of immune-based treatment across stages of bladder cancer, setting the foundation for even more personalized, durable, and curative care strategies in the years ahead.